Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq (florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio.
With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S. for the detection of beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline, according to the vendor. Neuraceq may also assist in assessing treatment eligibility for newly approved anti-amyloid drugs or for enrollment in clinical trials to further support drug development in neurodegenerative diseases, the company said.
The U.S. Food and Drug Administration (FDA) approved Neuraceq in 2014 as a radioactive diagnostic agent indicated for PET imaging of the brain in certain circumstances to estimate beta-amyloid neuritic plaque density in adult patients.
